Psychopharmacology

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

Retrieved on: 
Thursday, June 23, 2022
Patient, Lists of diseases, Psychiatry, Ketamine, Biotechnology, Therapy, Psychopharmacology, Research, Security (finance), Pharmaceutical industry

Investors participating in the conference who would like to schedule a one-on-one meeting with Pasitheas CEO may do so by contacting their H.C. Wainwright representative or registering HERE .

Key Points: 
  • Investors participating in the conference who would like to schedule a one-on-one meeting with Pasitheas CEO may do so by contacting their H.C. Wainwright representative or registering HERE .
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.
  • With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders.
  • Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Retrieved on: 
Tuesday, June 21, 2022
NIAAA, OTC Markets Group, Neuroimaging, Association, Department, Neuronus IBRO & IRUN Neuroscience Forum, Yale New Haven Hospital, Therapy, Translational neuroscience, American Association, Ketamine, Alcoholism, Psychopharmacology, Schizophrenia, National Center for Advancing Translational Sciences, The Company, Yale University, Translational research, Coronavirus Scientific Advisory Board (Turkey), Hebrew University of Jerusalem, Depression, Research, American Association for Laboratory Animal Science, Biological Psychiatry (journal), PTSD, Bar-Ilan University, CSE, Post-traumatic stress disorder, University, Eleazar Sukenik, Acquisition, Chicago (franchise), Mental health, FSE, GLOBE, Pharmaceutical industry, Medicine, Psychology, Neuroscience, Science, Psychiatry, Engineering

VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine.

Key Points: 
  • He is best known for leading the discovery of the rapid antidepressant effects of ketamine.
  • Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital.
  • He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
  • Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.

Free Children’s Mental Health Training for Pediatric Primary Care Providers

Retrieved on: 
Tuesday, June 7, 2022
Life, Caregiver, PTSD, Adult, REACH, Program, Oppositional defiant disorder, Psychosis, Mental health, Depression, ADHD, News, PPP, Psychopharmacology, ER, GLOBE, PCP, Bipolar disorder, Psychology, Pediatrics, American Academy of Child and Adolescent Psychiatry, Medicine, Atlanta metropolitan area

Since 2006, REACH has been training pediatric primary care providers (PCPs), therapists, and health care institutions nationwide, on the most advanced evidence-based childrens mental health therapies.

Key Points: 
  • Since 2006, REACH has been training pediatric primary care providers (PCPs), therapists, and health care institutions nationwide, on the most advanced evidence-based childrens mental health therapies.
  • Their flagship program, the Patient-Centered Mental Health in Pediatric Primary Care (PPP), trains providers to confidently diagnose, treat and manage common childrens mental health issues they see every day in practice, saving referrals to behavioral health specialists for more complex cases.
  • The more providers who are prepared to address both physical and mental health concerns, the better access will be to mental health care for hundreds of thousands of families who are sitting on waitlists for mental health care, or even worse trapped in the ER for days, weeks, even months for a spot to open up at a mental health treatment facility.
  • Their evidenced-based training programs equip primary care providers, mental health clinicians, health care institutions, educators, and caregivers on the most advanced therapies to better diagnose, treat and manage child and adult mental health issues.

VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting

Retrieved on: 
Thursday, June 2, 2022
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Benzodiazepine, Panic disorder, PTSD, Company, Research, Society, Anxiety, Marketing, Food, Central nervous system, Depression, Annual report, Pharmacist, Neuron, ASCP, PH94B, NIH, Annual general meeting, Nasdaq, Solution, Psychopharmacology, U.S. Securities and Exchange Commission, SAD, Divorce, Therapy, FDA, Brain, National, Central nervous system disease, Patient, Fast Track, Risk, PALISADE, Ajda, COVID-19, Social anxiety disorder, MOA, SEC, Prevalence, Clinical trial, Pharmacogenomics, Industry, Disorder, Psychiatry, Food and Drug Administration, CNS, Fear, Safety, Pharmaceutical industry

VistaGen is also currently evaluating PH94B in the Companys two PALISADE Phase 3 clinical trials for the acute treatment of anxiety in adults with social anxiety disorder (SAD).

Key Points: 
  • VistaGen is also currently evaluating PH94B in the Companys two PALISADE Phase 3 clinical trials for the acute treatment of anxiety in adults with social anxiety disorder (SAD).
  • There is significant demand and need for treatments for anxiety disorders, including adjustment disorder.
  • At this important moment and amid this significant unmet need, we look forward to sharing our clinical trial abstract with top psychopharmacology leaders in attendance at the ASCP Annual Meeting."
  • In addition to SAD, for which the FDA has granted Fast Track designation, PH94B may have potential in adjustment disorder with anxiety, procedural anxiety, PTSD, postpartum anxiety and panic disorder.

Discovery Behavioral Health Appoints Matthew Ruble, MD, As Chief Medical Officer

Retrieved on: 
Tuesday, May 31, 2022
Lists of diseases, Harvard Medical School, Addiction medicine, Hospital, Harvard University, Medicine, Happiness, Mental health, Patient, Psychiatry, Psychopharmacology, Associate, Education, Eating, Surgeon General of the United States, COVID-19, Adult, Grinnell College, DBH, Eating disorder, Pediatrics, Medical education, TMS, Comorbidity, University, School, CDC, Curriculum, Cambridge Health Alliance, United States drug overdose death rates and totals over time, CEO, Pharmaceutical industry, Humana, Discovery

LOS ANGELES, May 31, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc ., an expanding network of evidence-based mental health, substance use and eating disorder treatment centers, has appointed Matthew Ruble, M.D., a Harvard-trained psychiatrist, as Chief Medical Officer, reporting directly to DBH President & CEO John Peloquin.

Key Points: 
  • LOS ANGELES, May 31, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc ., an expanding network of evidence-based mental health, substance use and eating disorder treatment centers, has appointed Matthew Ruble, M.D., a Harvard-trained psychiatrist, as Chief Medical Officer, reporting directly to DBH President & CEO John Peloquin.
  • Most recently, he served as Lead Medical Director for Humana where he worked for seven years and created an innovative model of integrated medical and behavioral health and directed the clinical Utilization Management for Behavioral Health.
  • With the increasing integration of clinical practices with telehealth to provide comprehensive behavioral healthcare, Dr. Ruble envisions one of his objectives as Chief Medical Officer as strengthening the alliance between patient and provider.
  • He also completed his Chief Residency in Advanced Psychopharmacology and a Fellowship in Medical Education from Harvard Medical School.

Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions

Retrieved on: 
Thursday, May 19, 2022
Addiction, Eli Lilly and Company, Company, Public opinion, News, Patient, Person, SEDAR, Review, COVID-19, University, Intellectual property, Ketamine, Patent, Brain, Industry, Intention, Addictive behavior, Time, NEO, Perception, Forward-looking statement, DSM-5, Gambling in Thailand, FSE, Therapy, AUD, Phrase, Binge eating disorder, IP, Pharmaceutical industry, Security (finance), Psychopharmacology

Promising Results Merit Larger Study Which Awakn is Initiating

Key Points: 
  • The behavioral addictions included in the study were Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior.
  • The study investigated ketamine as a new treatment approach for these behavioral addictions by opening a window in which the brain can make new connections to change behavior.
  • The results from the study indicate the desired effects via potentially novel mechanisms and these results merit a larger study and further exploration, which Awakn is now initiating.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company researching, developing, and commercializing combined therapeutics to treat addiction, with a focus on Alcohol Use Disorder.

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

Retrieved on: 
Tuesday, April 26, 2022
Psychopharmacology, Family, Cancer, Genetic testing, Woman, Stroke, Degenerative disease, NASDAQ, Association for Molecular Pathology v. Myriad Genetics, Inc., Health, Anxiety, MYGN, Diagnosis, Life, GLOBE, Fast Company, Doctor of Philosophy, ADHD, Patient, MOST, Friends, Mental health, Fancher, Anger, SALT, Depression, Genetics, Parent, Myriad, Gene, HIV disease progression rates, Myriad Genetics, Physician, University, Risk, Precision medicine, Prequel, Medicine, Pharmaceutical industry, Medical device

Four out of 10 women without a diagnosis of depression or anxiety say they have reached or are reaching this point.

Key Points: 
  • Four out of 10 women without a diagnosis of depression or anxiety say they have reached or are reaching this point.
  • In fact, more than half (51%) of women diagnosed with anxiety and/or depression waited at least one year before seeking treatment or never sought treatment at all.
  • According to the survey, the top reasons women diagnosed with depression or anxiety delayed treatment are:
    Will my concerns be validated or ignored?
  • Less than half of women (44%) say they talk to friends or family to relieve stress and anxiety.

New Book by Psychiatrist and Mental Health Advocate Launches - The Promise of Psychedelics

Retrieved on: 
Friday, April 22, 2022
Psychopharmacology, Mental health, University, PTSD, Research, Anxiety, Science, GLOBE, Department, Bipolar disorder, Patient, Psychiatry, Ebook, Depression, Solution, Psychotherapy, Book, Addiction, Pharmaceutical industry, Medicine, Psychedelic drug

In The Promise of Psychedelics, Dr. Silverstone reveals why science tells us that combining certain psychedelics with the right psychotherapy can help individuals with a wide range of mental health problems, and why this multi-modal psychedelic-assisted psychotherapy promises to revolutionize the treatment of mental health disorders.

Key Points: 
  • In The Promise of Psychedelics, Dr. Silverstone reveals why science tells us that combining certain psychedelics with the right psychotherapy can help individuals with a wide range of mental health problems, and why this multi-modal psychedelic-assisted psychotherapy promises to revolutionize the treatment of mental health disorders.
  • Dr. Silverstone also shares the science behind micro-dosing psychedelics, which ones hold the most promise for inclusion in mental health therapies, and why some psychedelics simply aren't ready for prime time.
  • Dr. Peter Silverstone is a physician, neuroscientist, psychiatrist, entrepreneur, and author focused on designing and implementing new solutions to treat mental health disorders.
  • The Promise of Psychedelics, published by Ingenium Books , is available in eBook and paperback wherever you buy your books.

New Book by Psychiatrist and Mental Health Advocate, The Promise of Psychedelics, Launches Today

Retrieved on: 
Thursday, April 21, 2022
Psychopharmacology, Mental health, University, PTSD, Research, Anxiety, Science, GLOBE, Department, Bipolar disorder, Patient, Psychiatry, Ebook, Depression, Solution, Psychotherapy, Book, Addiction, Pharmaceutical industry, Medicine, Psychedelic drug

"We have a mental health system that is overwhelmed and underfunded, a psychiatric diagnosis framework that has major problems and doesn't allow for an individualized approach," said Dr. Silverstone.

Key Points: 
  • "We have a mental health system that is overwhelmed and underfunded, a psychiatric diagnosis framework that has major problems and doesn't allow for an individualized approach," said Dr. Silverstone.
  • "One out of every five adults experiences negative effects of conditions like PTSD, addiction, major depression, or anxiety.
  • Dr. Silverstone also shares the science behind micro-dosing psychedelics, which ones hold the most promise for inclusion in mental health therapies, and why some psychedelics simply aren't ready for prime time.
  • Dr. Peter Silverstone is a physician, neuroscientist, psychiatrist, entrepreneur, and author focused on designing and implementing new solutions to treat mental health disorders.

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

Retrieved on: 
Thursday, April 14, 2022
Psychopharmacology, Research, Ketamine, Psychiatry, Biotechnology, Patient, Therapy, Lists of diseases, Pharmaceutical industry

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

Key Points: 
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.
  • With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders.
  • Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.